ahlam1399
09-20-2015, 10:13 PM
Merck antibody reduces risk of C. difficile recurrence ? study
Sept 20 (Reuters) - An experimental antibody developed by Merck & Co Inc was shown in pivotal studies to reduce by about 10 percentage points the risk that infection with Clostridium difficile bacterium, which can cause a deadly diarrhea, will recur.
http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2.img (http://da.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/ach.img (http://adchoice.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/ach.htm)http://pi.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2t.imghttp://pi2.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4a02fcfc/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=zX8YZn8eywM:hIhRi-AebgU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zX8YZn8eywM:hIhRi-AebgU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=zX8YZn8eywM:hIhRi-AebgU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zX8YZn8eywM:hIhRi-AebgU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=zX8YZn8eywM:hIhRi-AebgU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/zX8YZn8eywM
Sept 20 (Reuters) - An experimental antibody developed by Merck & Co Inc was shown in pivotal studies to reduce by about 10 percentage points the risk that infection with Clostridium difficile bacterium, which can cause a deadly diarrhea, will recur.
http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2.img (http://da.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/ach.img (http://adchoice.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/ach.htm)http://pi.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2t.imghttp://pi2.feedsportal.com/r/238386017695/u/49/f/654213/c/35217/s/4a02fcfc/sc/14/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4a02fcfc/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=zX8YZn8eywM:hIhRi-AebgU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zX8YZn8eywM:hIhRi-AebgU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=zX8YZn8eywM:hIhRi-AebgU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=zX8YZn8eywM:hIhRi-AebgU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=zX8YZn8eywM:hIhRi-AebgU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/zX8YZn8eywM